Is Adagene Inc. (ADAG) a Buy, Sell, or Hold?
NASDAQ : ADAG
Adagene Inc. — News
$3.75 USD
-$0.14 (-3.6%)
- Volume
- 291.7K
- Average Volume
- 259.33K
- Market Capitalization
- $141.18M
- P/E Ratio
- -7.95
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $4.85
- Year Low
- $1.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.07
| Source | Headline |
|---|---|
|
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established globenewswire.com - 2026-08-12 07:30:00 |
|
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 2026-06-05 13:00:30 |
|
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year. zacks.com - 2026-06-02 10:41:10 |
|
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology. marketbeat.com - 2026-05-19 17:08:02 |
|
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY. globenewswire.com - 2026-05-12 08:30:00 |
